Monthly Archives: February 2022

THIS property may look fairly ordinary but there is more to it than meets the eye.

A clue that the Las Vegas home is not all as it appears is revealed in its asking price of a hefty $5.9million.

6

6

6

The Underground House at 3970 Spencer St, is mostly located 26-feet below the ground and was once a bomb shelter that has been turned into luxury home.

Covering 15,000-square feet, the property contains a pool, jacuzzi, casita, 500-feet of landscape murals, putting green and time-of-day lighting settings to copy the world outside the ceiling has twinkling stars to imitate the night sky.

It also comes with artificial trees, faux rocks and life-like scenery.

The main living space is accessed by an elevator from the structure above ground.

When you go down there, youre in a capsule and go back in time, Tee Thompson, a member of the secretive human life extension-enthusiast group Society for the Preservation of Near Extinct Species, toldthe Las Vegas Review-Journalin 2018 while living in the space on behalf of the society. I get to choose whether I want it day, night, dusk or dawn When it is dark, it is pitch black, and its very peaceful and quiet. I dont get to hear the outside elements. Its beautiful being down here. If youre not focused on what youre doing, you lose track of time.

The unusual home, situated 2.5miles east of the Strip, was built for personal use by investor Jerry Henderson, a subterranean living enthusiast, in 1978.

Henderson, who owned a company called Underground World Homes, also had a 45,000-square-foot underground home in Colorado.

He built two bedrooms and an 800-square-foot caretaker house into his sunless Las Vegas bunker, where he lived with his wife Mary until his death in 1983.

When Henderson died, Mary moved upstairs into the townhouse she built above the bunker and lived there until she passed away in 1989.

Following their deaths both properties were foreclosed on, the Review-Journal says.

The bunker was then bought for $1.15m by the Society in 2014, which made several renovations to the property.

Take an elevator ride down to an underground utopia, advertised the current listing, which also features a number of digital renderings showing a couple standing in front of the underground houses front doors, waving, the city street and sky above them.

6

6

6

We pay for your stories!

Do you have a story for The US Sun team?

Go here to read the rest:

This normal looking Las Vegas house has gone up for sale for $5.9million but can you spot its incredible... - The Sun

Intro : Dr. Anil Kukreja, Vice-President Medical Affairs & Regulatory, AstraZeneca India Ltd spoke to ETHealthworld's Prathiba Raju and elucidated how Evusheld is specifically intended to protect the most vulnerable populations, including immunocompromised patients. The vulnerable groups may receive limited or no protection from vaccines and currently have few options in the face of COVID-19 and remain at high-risk.

How does the first-ever monoclonal antibody cocktail work on immunocompromised patients and how the medicine aims to prevent Covid-19 infection in such patients?

Preventing immunocompromised individuals from getting COVID-19 rather than waiting to treat this vulnerable population once they become infected is an important goal in the fight against the pandemic. Evusheld is intended to protect the most vulnerable populations, including the immunocompromised, who may receive limited or no protection from vaccines and currently have few options in the face of the rapid rise in COVID-19 cases seen in recent weeks and remain at high-risk.

Evusheld is synthesised in a laboratory to mimic the bodys natural infection-fighting antibodies. Therapeutic antibodies can offer almost immediate protection by neutralizing the SARS-CoV-2 virus and activating an immune response. Evusheld is a combination of two long-acting monoclonal antibodies (mAbs) -tixagevimab and cilgavimab -derived from convalescent patients after SARS-CoV-2 virus. Each mAb was engineered with: AZs proprietary YTE half-life extension technology, which more than triples the durability of its action compared to conventional antibodies.The reduced Fc receptor binding technology to minimise the risk of antibody-dependent enhancement of disease.

It binds to distinct sites on the SARS-CoV-2 spike protein. The aim is that by targeting the spike protein, the antibody will neutralise the effects of the SARS-CoV-2 virus by affecting its capacity to infect healthy cells.

Evusheld (AZD7442) is a long-acting antibody (LAAB) combination, engineered with AstraZeneca's proprietary half-life extension technology to increase the therapy's durability upto 12 months, following a single administration. It has been designed to attach to the spike protein of SARS-CoV-2 at two different sites. In addition, Evusheld contains infection-fighting proteins called monoclonal antibodies. The half-life extension more than triples the durability of its action compared to conventional antibodies. It is specifically intended to protect the most vulnerable populations, including immunocompromised patients. The vulnerable groups may receive limited or no protection from vaccines and currently have few options in the face of COVID-19 and remain at high-risk.What is the status of availability of this antibody treatment in India? How will it help in containing the spread of COVID- 19? With most of the people in India with co-morbidities already taken first two doses of COVID vaccines and also administration booster shots, why should they take Evusheld?

We are committed to working with international and government agencies around the world to make Evusheld accessible so that countries can potentially add it to their arsenal to tackle COVID-19. Regulatory dossiers are being compiled per the requirements of various countries including India. We are sharing this emerging therapeutic option as evidence generated with stakeholders and seeking their insights to arrive at our strategy, regulatory filing and timelines.

It is the first long-acting antibody to demonstrate robust efficacy in both prevention and treatment of COVID-19. There is a growing body of evidence underlining the potential of our LAAB to make a real difference in the fight against COVID-19, especially for vulnerable populations. It showed robust, long-lasting protection against symptomatic COVID-19 that continues for at least six months, as demonstrated in the PROVENT Phase III trial. In PROVENT, Evusheld reduced the risk of developing symptomatic COVID-19 by 77 percent at the primary analysis and 83 percent at a six-month analysis compared to placebo.

What is its distinct cohort of compounds, can it contain all COVID-19 Variants of Concern?

Evusheld, is one of only two antibody therapies authorised for use to retain neutralising activity against all other variants of concern tested to date.At least, in the pre-clinical in vitro studies, we have seen that the antibody cocktail is active against all the strains that have been identified so far. The most recent study by USFDA also found it to be retaining the neutralising activity against Omicron variant.

It is said that a person receives two injections, it protects from the illness for only about 6 months, how many doses should be taken and the frequency. Does it differ as per the age? How effective is it for patients using immunosuppressants like long standing systemic steroids or chemotherapy?Preliminary data from a Phase I study show high neutralizing antibody titers for at least nine months, with potential to offer protection for up to 12 months following a single dose. Some information provided is based on a pre-print and has not undergone peer review.Do you think antiviral COVID-19 drugs should be seen as the next step in the fight against the virus, apart from vaccination?

No one vaccine or therapy can eliminate COVID-19, but multiple approaches could help to reduce the spread of the virus, defend those most vulnerable to infection, deliver better outcomes for patients and ultimately allow the world to return to normal.

Vaccines have the potential to provide long-term protection against COVID-19 but require a healthy immune system and can take a few weeks to generate a virus-specific immune response. While vaccines are helping people around the world,not everyone who receives a vaccine can produce antibodies,or produce antibodies at a level which is sufficient to protect them from COVID-19.These vulnerable populations may need added or more immediate protection.

Go here to see the original:

Evusheld adds a layer of protection to those with weakened immune systems - ETHealthworld.com

Under the changes, Sanofis sub brands, which include Sanofi Pasteur and Sanofi Genzyme, will be united under the Sanofi brand. Internally, staffers will continue to work under one of four global business units:Pasteur is the vaccines business unit and Genzyme is the specialty care business unit.The other two units are general medicine and consumer healthcare.

The refreshed branding represents the integrated way in which the company will work to achieve its ambition to transform the practice of medicine.

Sanofi embarked on these changes because itlost its stakeholders with multiple names,said Josep Catll, head of corporate affairs at Sanofi.

This is the only big pharma company remaining that still has such a broad portfolio. We want to be in every space that goes from prevention with vaccines to the more extreme, rare diseases of the other side of the business to everything in the middle from oncology to [multiple sclerosis]. Our portfolio is the result of 50 years of more than 500 mergers and acquisitions.

However, when Sanofi acquired a company, it didnt change the culture, look and feel of that companys purpose, with Catlla saying the company has been very fragmented over the last few years in that sense.

Sanofi wanted to find a theme that unites and connects all of its businesses and employees. The company listened to stakeholders both internally and externally, including healthcare and patient communities. Out of that, it came up with a new purpose, which is that Sanofi chases the miracle of science to improve peoples lives, said Catlla.

Some feedback it received: using the words miracle and science together may be seen as provocative since science is rational and data-driven and miracles are more aspirational.

Yes, science is very exact, but the effects of science can be super-emotional to the point where they are seen as a miracle, said Catll. For example, when paracetamol makes a bad headache go away, it can feel like a miracle to patients.

Sanofi used the word chasing in its purpose statement, because when a company chases something, it means it is determined and resilient to obtain it, said Catlla.

Sanofi wanted to get away from typical pharma jargon that leans on outcomes and impacting patients.

Improving peoples lives is more genuine to what we do, said Catll. In some cases, we cure, in others we bring better health or life extension, but in all the cases we bring hope to people.

Sanofi has also revealed a new logo,, which was inspired by the simple and motion-oriented codes of the tech industry, it said in a statement. The two purple dots embody the scientific journey between a starting point wondering what if? and a finish line. In other words, the eureka moment where innovative solutions are unlocked to impact peoples lives.

Sanofi started to think about itself differently when CEO Paul Hudson joined the company in 2019. That December, Sanofi launched its Play to Win strategy, which focuses on applying its platform for innovation to produce first- and best-in-class treatments and vaccines.

While business names are changing, the internal structure and reporting lines will remain the same and there will be no layoffs or people moves in relation to the changes.

This helps to position the comms team in a much more strategic manner throughout the company, Catll said.

To promote the rebranding, Sanofi is launching a series of films internally and externally with employees talking about the company to tell our own story, said Catll. Staffers discuss why they work at Sanofi and what they love about their jobs.

One employee is a scientist who had cancer, so she can talk to you as a researcher and also as a patient, said Catll. Others discuss how personal passions for dance and boxing link to their roles.

We have one single brand film now, but we will reveal individual stories of all the people in that film in the next few months so they can tell us more, said Catll.

Hudson sent a note to all employees on Thursday about the changes, including the brand film. Sanofi also rebranded all of its social media channels on Thursday.

Interpublic Group agency FutureBrand worked on the logo and Weber Shandwick and Jack Morton are aiding Sanofi with the launch.

Read the rest here:

Behind the scenes of pharmaceutical giant Sanofi's rebranding | Marketing - Campaign Asia

SPARTANBURG, S.C. (WSPA) Following delays, the city of Spartanburg said its project to extend the Mary Black Foundation Rail Trail will begin this year.

Over the past few years, those involved in the planning and development of the Rail Trail have run into roadblocks with the extension project.

Its been a lot of dealing with the South Carolina Department of Transportation. A lot of the trail goes along their right-of-way, said Spartanburg communications and marketing manager Christopher George. So, a lot of it has just been back and forth with them over their regulations and requirements and frankly a lot of this is stuff thats kind of new to them.

Delays have piled up along with residents hopes which, in return, were let down with no expected start date for expansion.

The city says its plan is still to extend the Rail Trail through downtown from its current end point at the intersection of Union Street and Henry Street.

This extension will allow its users a safe passage across the street; across Henry Street and all the way into downtown and eventually all the way to Barnet Park that will allow that connection for those folks using the railtrail to get to downtown, said Ned Barrett, trail development manager for Play. Advocate. Live Well. Spartanburg (PAL).

Developers said the new route will include space on Union Street, Kennedy Street and Converse Street, ending at Barnet Park. It will also include a first-of-its-kind in South Carolina curb-protected bike lane.

Along one section of it, which is alongConverse Streetto Barnet Park, well be narrowingsort ofthe roadway there and creating a protected cycle track. Andsowhat that isiswe will have a physical barrier between the trail and the oncoming traffic to protect cyclists and folks using the trail, said George.

According to PAL Spartanburg, since 2020, the trail count usage has tallied nearly 400,000 people.

Its a great change, the Rail Trail is the most popular recreational facility in the county, said Barrett.

People of all walks of life and all of our city uses it and, you know, if there is one complaint that folks have about is that its not long enough, George said.

Soon the Rail Trail will offer an extended space for usage.

We will be starting this spring. We dont have an exact start date yet, but we will be definitely be starting this spring on that extension, said George.

Read the original here:

Following delays, Spartanburgs Rail Trail extension set to begin this spring - WSPA 7News